Key Financial Data Of Group

Oncolys BioPharma Inc. - Filing #7611807

Concept As at
2021-12-31
2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
As at
2020-12-31
As at
2019-12-31
2019-01-01 to
2019-12-31
As at
2018-12-31
2018-01-01 to
2018-12-31
As at
2017-12-31
2017-01-01 to
2017-12-31
Key financial data of group
Business results of group
Net sales
642,494,000 JPY
314,179,000 JPY
1,303,844,000 JPY
168,549,000 JPY
229,139,000 JPY
Ordinary profit (loss)
-1,500,888,000 JPY
-1,723,537,000 JPY
-539,177,000 JPY
-1,230,105,000 JPY
-1,087,185,000 JPY
Net assets
3,593,992,000 JPY
2,003,325,000 JPY
3,454,048,000 JPY
2,901,153,000 JPY
2,931,893,000 JPY
Total assets
4,291,876,000 JPY
2,796,413,000 JPY
4,380,056,000 JPY
3,430,112,000 JPY
3,526,222,000 JPY
Net assets per share
206.86
136.43
240.71
216.61
263.54
Basic earnings (loss) per share
-95.50
-145.58
-65.55
-104.55
-106.23
Diluted earnings per share
Equity-to-asset ratio
0.836 xbrli:pure
0.714 xbrli:pure
0.787 xbrli:pure
0.843 xbrli:pure
0.829 xbrli:pure
Rate of return on equity
xbrli:pure
xbrli:pure
xbrli:pure
xbrli:pure
xbrli:pure
Price-earnings ratio
xbrli:pure
xbrli:pure
xbrli:pure
xbrli:pure
xbrli:pure
Net cash provided by (used in) operating activities
-1,741,827,000 JPY
-1,465,199,000 JPY
-238,228,000 JPY
-1,187,579,000 JPY
-1,096,840,000 JPY
Net cash provided by (used in) investing activities
-942,000 JPY
-37,577,000 JPY
-4,442,000 JPY
342,040,000 JPY
131,662,000 JPY
Net cash provided by (used in) financing activities
3,091,384,000 JPY
242,261,000 JPY
1,123,312,000 JPY
1,147,270,000 JPY
1,476,503,000 JPY
Cash and cash equivalents
3,209,635,000 JPY
1,822,850,000 JPY
3,097,514,000 JPY
2,218,074,000 JPY
1,922,454,000 JPY
Number of employees
33 xbrli:pure
32 xbrli:pure
27 xbrli:pure
30 xbrli:pure
29 xbrli:pure
Average number of temporary employees
3 xbrli:pure
5 xbrli:pure
5 xbrli:pure
6 xbrli:pure
6 xbrli:pure

Talk to a Data Expert

Have a question? We'll get back to you promptly.